TIRZEPATIDE

TIRZEPATIDE is a dual gip/glp-1 receptor agonist studied for metabolic research. Activates both GIP and GLP-1 receptors for enhanced metabolic effects. Published research has examined its role in weight loss, glucose regulation, insulin sensitivity.

Yes. Kirei Clinic ships TIRZEPATIDE to all Canadian provinces — Ontario, British Columbia, Alberta, Quebec, Manitoba, Saskatchewan, and all territories. It's available strictly for non-clinical laboratory research purposes.

Every batch is independently tested to 99%+ purity by third-party HPLC. Mass spectrometry confirms peptide identity. A Certificate of Analysis documenting purity, molecular weight, and batch data is included with every order.

Store lyophilized TIRZEPATIDE at -20°C in the original sealed vial. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles — aliquot if multiple uses are planned.

Draw bacteriostatic water into a syringe and inject slowly against the vial wall — not directly onto the powder. Swirl gently to dissolve; never shake. Common volumes are 1 mL, 2 mL, or 2.5 mL depending on the concentration needed. Let sit for a minute if not fully dissolved.

TIRZEPATIDE is legal to purchase in Canada for non-clinical laboratory research. It is not approved by Health Canada for therapeutic use and is not intended for human consumption. Kirei Clinic sells it strictly for research applications.

Both TIRZEPATIDE and semaglutide are used in metabolic research research but work through different mechanisms. TIRZEPATIDE is a dual gip/glp-1 receptor agonist. Researchers often study them in parallel to compare mechanism-specific effects.

Every order includes a Certificate of Analysis (COA) with: HPLC purity results (99%+), mass spectrometry data, batch number, manufacturing date, and expiry date. This provides full traceability for research records.